Replies to post #122372 on Biotech Values

[DewDiligence]

Thanks for rephrasing. If tweaked human insulin can be as good as—but not better than—insulin analogs, how does that make a compelling business proposition for the insulin *oligopolists?

*NVO, SNY, and LLY.